Search results
-
J&J sidelines a novel project
… about this project since patient deaths were reported at ASCO 2024, although at the time J&J said it was testing a …
- 05/19/2026 - 19:49 -
CCR8 promise and peril
… LaNova Cafelkibart PD-1 MAb Pooled ph1/2 data at ASCO 2024: 36% ORR (13/36) in gastric cancer + anti-PD-1; …
- 05/19/2026 - 19:49 -
Kainova bigs up EP4 antagonism
… Yuyao Ph1 in solid tumours completed Apr 2024 ASCO 2024 data: ORR 0% (0/14); YY001 will be combined with …
- 05/19/2026 - 19:49 -
SABCS 2025 – Carrick sees a way forward in CDK7
… Ph1/2 in solid tumours +/- Keytruda Data at ASCO 2024: 1 uPR among 18 pts TY-2699a TYK …
- 05/19/2026 - 19:49 -
Caribou finds a match
… at best in line with when this project disappointed at ASCO 2024. The data are important because vispa-cel, an …
- 05/19/2026 - 19:49 -
ESMO 2025 – Sanofi takes aim at Lutathera
… confirmed ORR; this is in line with results presented at ASCO 2024, and looks better than the 13% seen with Lutathera …
- 05/19/2026 - 19:49 -
J&J claims a Tecvayli/Darzalex combo win
… J&J’s GPRC5D-targeting T-cell engager Talvey. At ASCO 2024 the company presented results from a safety run-in …
- 05/19/2026 - 19:49 -
Astra pulls further ahead of Merck’s Curon project
… being represented in a Chinese phase 1 trial presented at ASCO 2024. Instead, data were reported solely in indolent …
- 05/19/2026 - 19:49 -
ESMO 2025 preview – Sanofi’s lead shot gets a boost
… received somatostatin analogue therapy, were presented at ASCO 2024. In a 36 patient-strong radioligand-naive cohort … N 36 26 Venue ASCO 2024 ESMO 2025 Cutoff date 28 May 2024 … meaningful” Source: company release & ASCO 2024. However, toxicity could be worth …
- 05/19/2026 - 19:49 -
Chia Tai keeps the TGF-β faith
… China ph1/2 in solid tumours; initial data at ASCO 2024: 6% ORR HCB301 HanchorBio Fusion …
- 05/19/2026 - 19:49
